Evaluation of the efficacy of polydeoxyribonucleotides in the healing process of autologous skin graft donor sites: a pilot study

In Valdatta et al. 2004, PDRN accelerated healing.

“PDRN accelerated healing, enhanced re-epithelialization, and reduced infection rates”

In Valdatta et al. 2004, PDRN enhanced re-epithelialization.

“PDRN accelerated healing, enhanced re-epithelialization, and reduced infection rates”

In Valdatta et al. 2004, PDRN reduced infection rates.

“PDRN accelerated healing, enhanced re-epithelialization, and reduced infection rates”

No adverse reactions to the PDRN ointment or its excipients were reported.

“No adverse reactions to the PDRN ointment or its excipients were reported.”

No infections were recorded in the PDRN ointment group, whereas nine infections occurred in the control group, representing a 45% infection rate.

“no infections were recorded in the PDRN group throughout the study period, whereas nine infections occurred in the control group, representing a 45% infection rate.”

Complete re-epithelialization occurred at a mean of 12.5 days (range 9-20) in the PDRN ointment group compared with 24.45 days (range 17-41) in the control group, representing an approximate 50% reduction in healing time.

“Complete re-epithelialization occurred at a mean of 12.5 days (range: 9-20) in the PDRN group compared with 24.45 days (range: 17-41) in the control group, representing an approximate 50% reduction in healing time.”

At day 15, mean re-epithelialization reached 98.5% (range 80-100%) in the PDRN ointment group compared with 53.5% (range 0-95%) in the control group (p<0.01).

“At day 15, the mean re-epithelialization reached 98.5% (range: 80-100%) in the PDRN group compared with 53.5% (range: 0-95%) in the control group (p<0.01).”

Valdatta et al. [9] was judged to have a high overall risk of bias due to absence of blinding, potential bias in outcome measurement, and manufacturer sponsorship.

“Valdatta et al. [9] was judged to have a high overall risk of bias due to the absence of blinding, potential bias in outcome measurement, and manufacturer sponsorship.”

At day 7, mean re-epithelialization was 46.75% (range 0-90%) in the PDRN ointment group compared with 19.25% (range 0-55%) in the control group (p<0.01).

“At day 7, the mean percentage of re-epithelialization was 46.75% (range: 0-90%) in the PDRN group compared with 19.25% (range: 0-55%) in the control group (p<0.01).”

PDRN-treated patients were nearly completely asymptomatic, with only four cases of moderate symptoms, while the control group included four cases of serious symptoms and nine cases of marked symptoms.

“Subjective symptom assessment demonstrated that PDRN-treated patients were nearly completely asymptomatic, with only four cases of moderate symptoms reported, while the control group included four cases of serious symptoms and nine cases of marked symptoms”